Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aduhelm Adverse Event Reports Come In, Another Potential Hurdle To Uptake

Executive Summary

One patient treated with Aduhelm died who was diagnosed with cerebral edema thought to be ARIA-E, a known risk, Biogen confirmed.

You may also be interested in...



Aduhelm Label Update Includes Seizure Risk And Recommends More MRIs

New safety information may help defense of CMS's coverage restrictions. FDA updated the prescribing information for Biogen’s Alzheimer's therapy after four cases of seizures were reported in a trial.

Aduhelm Label Update Includes Seizure Risk And Recommends More MRIs

FDA updated the prescribing information for Biogen’s Alzheimer's therapy after four cases of seizures were reported.

Biogen Fires Back At Critics In Defense Of Aduhelm

Management tried to sidestep controversy around the approval of Aduhelm and said it remains confident the drug will be reimbursed.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel